Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CFLAR_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CFLAR_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CFLAR_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CFLAR_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CFLAR_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CFLAR_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CFLAR_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007084924 | Skin | cSCC | response to epidermal growth factor | 27/4864 | 49/18723 | 1.38e-05 | 1.73e-04 | 27 |
GO:007136424 | Skin | cSCC | cellular response to epidermal growth factor stimulus | 25/4864 | 45/18723 | 2.37e-05 | 2.72e-04 | 25 |
GO:007155917 | Skin | cSCC | response to transforming growth factor beta | 95/4864 | 256/18723 | 5.21e-05 | 5.31e-04 | 95 |
GO:007156025 | Skin | cSCC | cellular response to transforming growth factor beta stimulus | 92/4864 | 250/18723 | 9.65e-05 | 8.99e-04 | 92 |
GO:007137518 | Skin | cSCC | cellular response to peptide hormone stimulus | 104/4864 | 290/18723 | 1.15e-04 | 1.06e-03 | 104 |
GO:190204123 | Skin | cSCC | regulation of extrinsic apoptotic signaling pathway via death domain receptors | 25/4864 | 49/18723 | 1.53e-04 | 1.35e-03 | 25 |
GO:1901653110 | Skin | cSCC | cellular response to peptide | 124/4864 | 359/18723 | 1.75e-04 | 1.49e-03 | 124 |
GO:000862522 | Skin | cSCC | extrinsic apoptotic signaling pathway via death domain receptors | 36/4864 | 82/18723 | 3.22e-04 | 2.57e-03 | 36 |
GO:0032869110 | Skin | cSCC | cellular response to insulin stimulus | 75/4864 | 203/18723 | 3.53e-04 | 2.78e-03 | 75 |
GO:003134622 | Skin | cSCC | positive regulation of cell projection organization | 120/4864 | 353/18723 | 4.49e-04 | 3.44e-03 | 120 |
GO:0032868110 | Skin | cSCC | response to insulin | 93/4864 | 264/18723 | 5.10e-04 | 3.83e-03 | 93 |
GO:0051384110 | Skin | cSCC | response to glucocorticoid | 57/4864 | 148/18723 | 5.30e-04 | 3.97e-03 | 57 |
GO:0031960110 | Skin | cSCC | response to corticosteroid | 63/4864 | 167/18723 | 5.35e-04 | 3.97e-03 | 63 |
GO:0071453111 | Skin | cSCC | cellular response to oxygen levels | 66/4864 | 177/18723 | 5.79e-04 | 4.21e-03 | 66 |
GO:005067324 | Skin | cSCC | epithelial cell proliferation | 144/4864 | 437/18723 | 6.07e-04 | 4.38e-03 | 144 |
GO:0043280111 | Skin | cSCC | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 50/4864 | 129/18723 | 9.55e-04 | 6.47e-03 | 50 |
GO:200037719 | Skin | cSCC | regulation of reactive oxygen species metabolic process | 58/4864 | 157/18723 | 1.55e-03 | 9.60e-03 | 58 |
GO:200105624 | Skin | cSCC | positive regulation of cysteine-type endopeptidase activity | 55/4864 | 148/18723 | 1.73e-03 | 1.06e-02 | 55 |
GO:190165514 | Skin | cSCC | cellular response to ketone | 38/4864 | 96/18723 | 2.38e-03 | 1.38e-02 | 38 |
GO:002261221 | Skin | cSCC | gland morphogenesis | 45/4864 | 118/18723 | 2.43e-03 | 1.39e-02 | 45 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CFLAR | SNV | Missense_Mutation | | c.670N>A | p.Val224Met | p.V224M | O15519 | protein_coding | deleterious(0.04) | possibly_damaging(0.798) | TCGA-AN-A0AM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CFLAR | SNV | Missense_Mutation | novel | c.1152N>C | p.Glu384Asp | p.E384D | O15519 | protein_coding | tolerated(0.56) | benign(0.003) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CFLAR | SNV | Missense_Mutation | novel | c.565G>T | p.Ala189Ser | p.A189S | O15519 | protein_coding | tolerated(1) | benign(0) | TCGA-EW-A423-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
CFLAR | insertion | In_Frame_Ins | novel | c.1150_1151insTTTTCCCCAGAGCTTCTTCGAGACACCTTC | p.Glu384delinsValPheProArgAlaSerSerArgHisLeuGln | p.E384delinsVFPRASSRHLQ | O15519 | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CFLAR | insertion | Nonsense_Mutation | novel | c.700_701insCACTGTAGCCAGACTGCCTCTCTAGA | p.Phe234SerfsTer3 | p.F234Sfs*3 | O15519 | protein_coding | | | TCGA-ZJ-A8QQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
CFLAR | SNV | Missense_Mutation | | c.1143G>T | p.Lys381Asn | p.K381N | O15519 | protein_coding | tolerated(0.4) | benign(0.015) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CFLAR | SNV | Missense_Mutation | | c.877N>A | p.Leu293Ile | p.L293I | O15519 | protein_coding | tolerated(0.08) | possibly_damaging(0.906) | TCGA-AA-A01Z-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
CFLAR | SNV | Missense_Mutation | novel | c.803N>A | p.Arg268Gln | p.R268Q | O15519 | protein_coding | tolerated(0.36) | benign(0.003) | TCGA-G4-6320-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD |
CFLAR | SNV | Missense_Mutation | | c.653N>A | p.Gly218Asp | p.G218D | O15519 | protein_coding | tolerated(0.56) | benign(0) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CFLAR | SNV | Missense_Mutation | novel | c.191N>A | p.Arg64Gln | p.R64Q | O15519 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8837 | CFLAR | DRUG RESISTANCE, DRUGGABLE GENOME, PROTEASE | | BAY-11-7085 | BAY-11-7085 | 22326395 |
8837 | CFLAR | DRUG RESISTANCE, DRUGGABLE GENOME, PROTEASE | | DEHYDROEQUOL | IDRONOXIL | |
8837 | CFLAR | DRUG RESISTANCE, DRUGGABLE GENOME, PROTEASE | | FINASTERIDE | FINASTERIDE | 11399535 |
8837 | CFLAR | DRUG RESISTANCE, DRUGGABLE GENOME, PROTEASE | | BICALUTAMIDE | BICALUTAMIDE | 22623731 |
8837 | CFLAR | DRUG RESISTANCE, DRUGGABLE GENOME, PROTEASE | | NINTEDANIB | NINTEDANIB | |
8837 | CFLAR | DRUG RESISTANCE, DRUGGABLE GENOME, PROTEASE | | CABOZANTINIB | CABOZANTINIB | |
8837 | CFLAR | DRUG RESISTANCE, DRUGGABLE GENOME, PROTEASE | | DOVITINIB | DOVITINIB | |